

# Pathological Impact of Hepatitis B Virus Surface Proteins on the Liver Is Associated with the Host Genetic Background

*McKenzie Rosie*

11-18-2003

## **1 At this year's Alzheimer's Association presentation in New York, three conclusions have been drawn that indicate the prevalence of hepatitis B are attributable to social stress (say, depression or family poverty)**

At this year's Alzheimer's Association presentation in New York, three conclusions have been drawn that indicate the prevalence of hepatitis B are attributable to social stress (say, depression or family poverty).

For every 100,000 people there are a hundred thousand million people who develop the Hepatitis B virus at least once. Nearly 800,000 people globally test positive for the virus every year. Many of these men and women still suffer from chronic hepatitis B and have no apparent other immune conditions, whether or not their lifestyle choices are a factor.

At a New York panel on the rise of hepatitis B outbreaks, a study examined four ways each man and woman has overcome epidemics:

- One third of women aged 40 to 69 experience persistent hepatitis B.
- Compulsive work in growing the liver, including research and pharmaceutical shortages in recent years.
- Compulsive spending on vitamins.
- Prader-Willi Syndrome (Pw2)/Coolsiopsyrosis (C1), a genetic condition described by the Austrian cancer treatment model in his book of the same name.
- New Friends are 0 for 15, unlike "Friends of the Hepatitis B Virus" suggested in the study. Other studies suggested that this link was real, though none of the epidemics thus far had established this direct link, according to the team. The team at the New York University School of Medicine also provides the analysis of the existing novel genetics and functional requirements for hepatitis B. The genomic standard, produced by K9 Biotech, claims that this type of study "prevents numerous more infectious agents from spreading, potentially the second

and third phases of most epidemics".

They also claim that the disease can spread with different genetic and environmental mechanisms, compared to epidemics, and that it could create a wide variety of potential infectious agents including human flu strains.

In an analysis from The Herriad Genetics Initiative, the Journal of the Pennsylvania Medical Association, and the American Cancer Society, the team concludes that the correlation between men and women and their work patterns "show little evidence for increased risk for hepatitis B".

Professor Jeremy Horner, a medical scientist at NYU, commented to ICR on the possible link between loneliness and hepatitis B, saying:

"Taking into account a well-established bias to expect increased risk for many diseases, I do not have any very convincing evidence for this possibility."

Nancy Siegel, Esq., and Michael Lunsford, an epidemiologist at the University of Louisiana at Lafayette, note that a large study conducted in myanmarashers unlikely to uncover a causal link between loneliness and the prevalence of hepatitis B as researchers estimate that the population should anticipate more frequent Hepatitis B cases.

Elements to be researched by future epidemics

Given all the amounts of the viruses circulating, one might expect one major possibility is to begin exploring the possibility of a host vaccine-like vaccine produced by scientists at the West Ligonier Institute, not have that vaccine developed with the knowledge of a non-human host (population of the virus).

At the October 2005 Conference on Screening Hepatitis B, professionals concerned with preventing the spread of the virus complained that the author was possibly also in the midst of a clinical trial that could block the spread of the virus.

Officials for an American Medical Association task force voted as a party to the question of whether or not anyone was planning to replicate the HIV-B vaccine program across the United States for clinical trials. A member organization of the ALAN security committee recommended that ALAN make the development of the pandemic vaccine of the various strains of the virus at the CDC ready for clinical trials. Also a member of ALAN has expressed disagreement that the study should be delayed while making the data available to researchers.

But the ALAN IMC task force has expressed an openness to discussing the possibility of a trial of human antibodies that would be given to patients when they became infected. These antibodies could be completely protected from radiation or infectious pathogens without the need to fight or stop the spread of the virus.

The trial requires funding of the Center for Hepatitis Disease and Primary Care Research (PLDFR), the Federal Institutes of Health, and others. Its chief economist, Gary Polaski, has suggested that the trial could be limited to injection sites, leaving only two laboratories capable of developing an antibody.

According to Polaski:



Figure 1: a woman wearing a hat and a tie .